Levossimendano Reig Jofre

Levosimendan, the active ingredient in Levossimendano Reig Jofre, is a calcium sensitizer presented as an intravenous solution for intravenous use. It is employed to improve cardiac performance in patients with acute decompensated heart failure. GNH USA supplies Levossimendano Reig Jofre as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Levosimendan is used in the management of acute decompensated heart failure, a condition characterized by sudden worsening of cardiac function. - Acute decompensated heart failure: enhances myocardial contractility and reduces symptoms of low output, helping stabilize the patient.

Levosimendan may be associated with several adverse reactions that clinicians monitor during therapy.

Common Side Effects: - Hypotension: drop in blood pressure, especially during initial infusion. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Tachycardia: increased heart rate. - Dizziness: feeling of light‑headedness.

Serious or Rare Side Effects: - Arrhythmias: potentially life‑threatening rhythm disturbances. - Severe hypotension: marked blood pressure fall requiring intervention. - Myocardial ischemia: reduced blood flow to heart muscle. - Allergic reactions: rash, pruritus, or anaphylaxis. - Pulmonary edema: fluid accumulation in lungs.

Levosimendan requires careful patient assessment and monitoring before and during administration. - Cardiovascular monitoring: continuously observe blood pressure and heart rate. - Renal impairment: adjust infusion rate and monitor renal function. - Hepatic dysfunction: use with caution in patients with liver disease. - Concomitant vasodilators: increased risk of excessive hypotension. - Electrolyte imbalance: correct potassium and magnesium levels prior to infusion. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levosimendan can interact with other cardiovascular agents, necessitating vigilance.

Major Interactions (Avoid): - Sodium nitroprusside: additive vasodilatory effect leading to profound hypotension. - Phosphodiesterase inhibitors: may cause severe hypotension and arrhythmias. - Other calcium sensitizers: risk of excessive inotropic stimulation.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt desired inotropic response. - ACE inhibitors: combined effect on blood pressure requires monitoring. - Diuretics: may exacerbate electrolyte disturbances and hypotension.